Implant comprising FGF-18

Patent metadata

Field	Value
Publication number	US-10086112-B2
Application number	US-201515120137-A
Country	US
Kind code	B2
Filing date	Feb 20, 2015
Priority date	Feb 20, 2014
Publication date	Oct 2, 2018
Grant date	Oct 2, 2018

Abstract

The invention relates to the field of pharmaceutical compositions. More particularly it is directed to substance delivery system (or implant), such as scaffolds and membranes, comprising an anabolic drug, such as a Fibroblast Growth Factor 18 (FGF-18) compound, to methods of producing such delivery system, as well as use thereof. The implants according to the invention are for use for the treatment of cartilage disorders, such as osteoarthritis, cartilage injury or osteochondral defects.

First claim

The invention claimed is:

1. A substance delivery system comprising at least one polymeric material forming a matrix and an anabolic drug, wherein the at least one polymeric material comprises collagen and wherein said anabolic drug is included in the at least one polymeric material forming the matrix, wherein the matrix is a biphasic scaffold or a biphasic membrane, and wherein the anabolic drug is an FGF-18 polypeptide comprising SEQ ID NO: 1 or a fragment thereof having chondrocyte or osteoblast proliferation activity or cartilage formation activity, and wherein the anabolic drug is present at a dose from 20 to 100 mcg/system.

2. The substance delivery system according to claim 1 , wherein the at least one polymeric material is a combination of collagen and glycosaminoglycan (GAG).

3. The substance delivery system according to claim 1 , which further comprises chondrogenic cells.

4. The substance delivery system according to claim 1 , wherein the FGF-18 polypeptide is selected from the group consisting of:
a) a polypeptide comprising residues 28-207 of SEQ ID NO:1, and
b) a polypeptide comprising SEQ ID NO:2.

5. A process for producing the substance delivery system according to claim 1 , which comprises the steps of: a) preparing the matrix comprising at least one polymeric material, and b) adding the anabolic drug to the matrix prepared in step a), wherein said anabolic drug is included in the at least one polymeric material forming the matrix.

6. The process according to claim 5 which further comprises a step c) of adding chondrogenic cells to the matrix prepared in step a).

7. A method of treating a cartilage damage comprising administering the substance delivery system of claim 1 to a subject in need of treatment.

8. The method according to claim 7 , wherein the cartilage damage is due to a cartilage disorder i& selected from osteoarthritis, cartilage injury and osteochondral defects.

9. The method according to claim 7 , wherein the substance delivery system is administered to a patient in need of said treatment via a transplantation procedure.

10. An article of manufacture comprising the substance delivery system according to claim 1 .

11. The article of manufacture according to claim 10 , wherein each of the components are combined either before implantation or after implantation.

Assignees

• Merck Patent Gmbh

Inventors

• Ladel Christoph H
• Guehring Hans

Classifications

• A61P19/00

  Drugs for skeletal disorders · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61L27/26

  Mixtures of macromolecular compounds · CPC title

• A61K38/18

  Growth factors; Growth regulators · CPC title

• A61L27/24

  Collagen · CPC title